— Know what they know.
Not Investment Advice

MLC.IR DUB

Malin Corporation plc
1W: +0.0% 1M: +0.0% 3M: -3.5% YTD: -11.4% 1Y: -12.5% 3Y: +52.8% 5Y: +2.9%
€7.00 ($7.88)
+0.00 (+0.00%)
 
DUB · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 48 · €30.3M mcap · 2M float · 0.0068% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap€30.3M ($34.1M)
52W Range6.8-9.3
Volume73
Avg Volume139
Beta0.42
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFiona Dunlevy
Employees2
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2014-03-25
The Lennox Building
Dublin, DU D02 FK02
IE
353 1 901 5700
About Malin Corporation plc

Malin Corporation plc operates as a life sciences firm across Ireland and the United States, primarily through its various subsidiaries. The company specializes in developing and delivering vital solutions for critical medical challenges. Its portfolio includes groundbreaking cell and gene therapies aimed at patients with significant unmet medical requirements. Furthermore, Malin provides treatments targeting pressing needs in oncology, infectious diseases, and autoimmune conditions. It also addresses specific women's health concerns, such as recurrent vulvovaginal candidiasis, and offers remedies for fungal nail infections like onychomycosis. Beyond these, Malin's offerings extend to pharmaceutical products for protein misfolding disorders, a sophisticated platform designed to identify pathogenic bacteria within the gut microbiome, and advanced UV-light disinfection technologies. Additionally, it offers corporate secretarial services. Established in 2014, Malin Corporation plc maintains its headquarters in Dublin, Ireland.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms